Continuous glucose monitor

Rimidi Achieves 72% Revenue Growth, Grows Client Base by 141% in 2021

Retrieved on: 
Tuesday, February 1, 2022
Growth, Risk, Patient, Emory Healthcare, Abbott, Gaps, MD, Boston Medical Center, Twitter, EHR, Technology, Continuous glucose monitor, COVID-19, Alivecor, Nextgen, Smart, Health, RPM, Patient-reported outcome, News, Doctor of Philosophy, Pros, New, LinkedIn, Solution, Pharmaceutical industry, Medicine, Sales, Facebook

ATLANTA, Feb. 1, 2022 /PRNewswire-PRWeb/ -- Rimidi , a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, today announced that the company increased its revenue by 72% and grew its client base by triple digits in 2021.

Key Points: 
  • ATLANTA, Feb. 1, 2022 /PRNewswire-PRWeb/ -- Rimidi , a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, today announced that the company increased its revenue by 72% and grew its client base by triple digits in 2021.
  • Specifically, in 2021 Rimidi grew its number of EHR integrations by 275%, with the greatest growth among clients with Epic and NextGen EHRs.
  • For more information on Rimidi, its solutions, and to stay abreast of upcoming news and updates, visit http://www.rimidi.com and follow the company on Twitter @JointheRimidi .
  • Created by doctors, Rimidi's leading clinical management platform empowers healthcare organizations to optimize clinical workflows, enhance patient experiences and achieve quality objectives.

Asia Pacific Continuous Glucose Monitoring Market Analysis, Estimations & Forecasts, 2017-2020 & 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021
Diabetes, Health, Medical Devices, Therapy, IDF, FDA, Diabetes, Conditional sentence, GlySens ICGM, Child, Component, Awareness, Population, Growth, Adult, Intensive care unit, International Diabetes Federation, Continuous glucose monitor, Medtronic, Incidence, USD, Adoption, Freestyle, IPhone, CAGR, Abbott Laboratories, Abbott, Johnson & Johnson, Prevalence, Estimation, ASEAN, Demography, FreeStyle, CGM, Dexcom, IOS, Coal, Medical device, Pharmaceutical industry

The "Asia Pacific Continuous Glucose Monitoring Market, By Component, By Demographics, By End User, Estimation & Forecast, 2017 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Continuous Glucose Monitoring Market, By Component, By Demographics, By End User, Estimation & Forecast, 2017 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Asia Pacific Continuous Glucose Monitoring (CGM) market held a market value of USD 1,081.6 Million in 2021 and is projected to reach USD 2,967.2 Million by the year 2030.
  • Continuous Glucose Monitors (CGM) are devices used for monitoring blood glucose continuously.
  • By country, the Asia Pacific Continuous Glucose Monitoring (CGM) market is divided into China, India, Japan, South Korea, Australia & New Zealand, Indonesia, ASEAN, and the Rest of Asia Pacific.

Cue Health Appoints Nitin Duggal as Chief Marketing Officer

Retrieved on: 
Thursday, December 16, 2021
Health, Hand, PSAR, FDA, Health Canada, Central Drugs Standard Control Organisation, Dartmouth, McKinsey & Company, Business, Growth, Interim order, Outline of health sciences, Telecommunication, SAN, Nasdaq, National FongShan Senior Commercial & Industrial Vocational School, COVID-19, CEO, Health Sciences Authority, Marketing, Continuous glucose monitor, Nitin, CE, Tuck School of Business, Multimedia, MBA, Union, Senior, Silicon, Cassette tape, Pharmaceutical industry, Electronics, Cue

SAN DIEGO, Dec. 16, 2021 /PRNewswire/ --Cue Health Inc. ("Cue") (Nasdaq: HLTH), a health technology company, today announced that it has appointed Nitin Duggal as its first Chief Marketing Officer, effective immediately.

Key Points: 
  • SAN DIEGO, Dec. 16, 2021 /PRNewswire/ --Cue Health Inc. ("Cue") (Nasdaq: HLTH), a health technology company, today announced that it has appointed Nitin Duggal as its first Chief Marketing Officer, effective immediately.
  • Nitin joins Cue to help further strengthen the company's brand, marketing, and technology capabilities across its virtual care platform and products.
  • "On behalf of everyone at Cue, I'm thrilled to welcome Nitin to Cue.
  • Cue Health (Nasdaq: HLTH) is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care.

Bigfoot Clinic Hub™ Puts Critical Data at Fingertips of Health Care Professionals to Enable Proactive Care of their Patient Populations with Type 1 and Type 2 Diabetes

Retrieved on: 
Wednesday, December 1, 2021
Technology, Medical Devices, Venture Capital, Diabetes, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Data Management, Patient, Caregiver, Insulin, CGM, Review, Unity, Hypoglycemia, Contraindication, Geography, Technology, Time, Diabetes, Hearing, Compliance, Health, HCPS, Bigfoot Biomedical, Injection, CPT, Program, Education, Continuous glucose monitor, MDI, Wi-Fi, Physician, CGMS-A, Endocrinology, AID, Type 1, Data, FreeStyle, Instagram, Â, HCP, RPM, Person, Multimedia, Hyperglycemia, Bigfoot, AGP, Pharmaceutical industry, Medical device, Medicine, Health insurance

MDI insulin therapy is common for patients with either Type 1 or Type 2 diabetes.

Key Points: 
  • MDI insulin therapy is common for patients with either Type 1 or Type 2 diabetes.
  • With Bigfoot Unity, HCPs are able to review, on demand, patient data derived from the patients prescribed Bigfoot Unity System.
  • In designing Clinic Hub, Bigfoot focused on creating a streamlined, patient report format to provide meaningful, at-a-glance data.
  • Bigfoot Biomedical was founded by a team of people with personal connections to Type 1 and Type 2 diabetes.

Two-Thirds of US Doctors Say Mobile Diabetes Apps Help Patients Stay In Touch with Disease Management, In New InCrowd Instant Insights Data

Retrieved on: 
Wednesday, December 1, 2021
Data Management, Health, Infectious Diseases, Technology, Other Technology, Software, General Health, Patient, Caregiver, American Association of Clinical Endocrinologists, CEO, Industry, Diabetes, Acquisition, PCP, Exercise, CLARITY, Holiday, Health, Diet, MHealth, Continuous glucose monitor, Weight loss, Physician, Research, Mark (given name), MyFitnessPal, Acnalbasac Noom, Motivation, CA, Disease management, Maintenance, Mobile diabetes screening initiative, Life, Allied Healthcare, Medical device

However, just 53% agree that patients using mobile apps have better health outcomes, and 50% say that they encourage all their T2D patients to use mobile diabetes apps to track their health.

Key Points: 
  • However, just 53% agree that patients using mobile apps have better health outcomes, and 50% say that they encourage all their T2D patients to use mobile diabetes apps to track their health.
  • Although only a quarter (26%) report difficulty with patients adopting diabetes mobile apps, ease of use remains an important issue for many patients.
  • Just 23% of physicians agree that their T2D patients are tech savvy enough to use diabetes mobile apps.
  • In verbatim reports many physicians cite mobile apps as a game-changer for their patients, while some say their younger patients are able to use mobile diabetes apps to better effect.

Asia's First Data Integration of Health Management App and CGM Data

Retrieved on: 
Wednesday, November 17, 2021
CGM, Behavior, Blood pressure, Caregiver, General manager, Entrepreneurship, CEO, Diet, Self-management, Exercise, IIT, Partnership, Patient, Environment, Glucose, Continuous glucose monitor, Diabetes Care, Diabetes, Medical device, Pharmaceutical industry

TAIPEI, Nov. 16, 2021 /PRNewswire/ -- Health2Syncannounced today to launcha new version of its mobile app thatintegrates continuous glucose monitoring (CGM) data from Abbott's FreeStyle Libre.

Key Points: 
  • TAIPEI, Nov. 16, 2021 /PRNewswire/ -- Health2Syncannounced today to launcha new version of its mobile app thatintegrates continuous glucose monitoring (CGM) data from Abbott's FreeStyle Libre.
  • This will be the first of its kind in Japan to integrate CGM data along with other health data on a single app.
  • This data integration will allow people living with diabetes to view their diet, weight, blood pressure, exercise, and other data along with CGM data in the Health2Sync app, enabling comprehensive health management for people with diabetes.
  • In 2021, FreeStyle Libre Link was launched as Japan's first mobile app to enable discrete diabetes management with smartphone scanning.

Asia's First Data Integration of Health Management App and CGM Data

Retrieved on: 
Wednesday, November 17, 2021
CGM, Behavior, Blood pressure, Caregiver, General manager, Entrepreneurship, CEO, Diet, Self-management, Exercise, IIT, Partnership, Patient, Environment, Glucose, Continuous glucose monitor, Diabetes Care, Diabetes, Medical device, Pharmaceutical industry

TAIPEI, Nov. 17, 2021 /PRNewswire/ -- Health2Sync announced today to launch a new version of its mobile app that integrates continuous glucose monitoring (CGM) data from Abbott's FreeStyle Libre®. This will be the first of its kind in Japan to integrate CGM data along with other health data on a single app.

Key Points: 
  • TAIPEI, Nov. 17, 2021 /PRNewswire/ -- Health2Syncannounced today to launcha new version of its mobile app thatintegrates continuous glucose monitoring (CGM) data from Abbott's FreeStyle Libre.
  • This will be the first of its kind in Japan to integrate CGM data along with other health data on a single app.
  • This data integration will allow people living with diabetes to view their diet, weight, blood pressure, exercise, and other data along with CGM data in the Health2Sync app, enabling comprehensive health management for people with diabetes.
  • In 2021, FreeStyle Libre Link was launched as Japan's first mobile app to enable discrete diabetes management with smartphone scanning.

Abbott and the American Diabetes Association® Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology

Retrieved on: 
Tuesday, November 9, 2021
Quality of life, Mortality, ADA, Health education, American Diabetes Association, Healthcare disparity in Massachusetts, Color, Health, Ohio State University, Education, Health Resources and Services Administration, Technology, Diabetes, Research, Program, Partnership, Endocrinology, Awareness, Metabolism, Solution, Glucose, LinkedIn, Continuous glucose monitor, Prenatal nutrition, National Center for Integrative Biomedical Informatics, Connected for Life, NYSE, Time, FreeStyle, Life, Risk, Health equity, Pharmaceutical industry, Medical device

ABBOTT PARK, Ill. and ARLINGTON, Va., Nov. 9, 2021 /PRNewswire/ --Abbott (NYSE: ABT) and the American Diabetes Association (ADA) announced today the launch of their first joint community health partnership.

Key Points: 
  • ABBOTT PARK, Ill. and ARLINGTON, Va., Nov. 9, 2021 /PRNewswire/ --Abbott (NYSE: ABT) and the American Diabetes Association (ADA) announced today the launch of their first joint community health partnership.
  • The program seeks to better understand and address healthcare disparities for people of color living with diabetes, while fostering accessibility of diabetes care technology within the community.
  • "Diabetes is one of the most pressing health issues of our time, particularly for people of color," said Charles Henderson, chief advocacy officer of the American Diabetes Association.
  • About the American Diabetes Association:
    The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive.

Diabetes Awareness Month reminds Canadians to take action with regular eye care to avoid vision loss

Retrieved on: 
Tuesday, November 9, 2021
People, Quality of life, Royal College of Physicians and Surgeons of Canada, Government, Blood pressure, Royal college, Eye disease, American Ophthalmological Society, Diabetic retinopathy, Eye, CEO, Continuous glucose monitor, DR, Disease, Prediabetes, Blood, Canadian Medical Association, RCPSC, Professional development, Diabetes, Research, Severe cognitive impairment, Insulin, CPD, Awareness, COS, CMA, Surgeon, Glucose, Health policy, Ophthalmology, Physician, Diabetes Canada, Cholesterol, Pancreas, Risk, Zombie Awareness Month, Retina, Pharmaceutical industry, Health insurance, Medical device

To help spread awareness during Diabetes Awareness Month and to mark this year's 100th anniversary of the discovery of insulin the Canadian Ophthalmological Society has partnered with Diabetes Canada once again to highlight the importance of regular eye care for preventing vision loss.

Key Points: 
  • To help spread awareness during Diabetes Awareness Month and to mark this year's 100th anniversary of the discovery of insulin the Canadian Ophthalmological Society has partnered with Diabetes Canada once again to highlight the importance of regular eye care for preventing vision loss.
  • The theme of Diabetes Canada's Diabetes Awareness Month campaign is "Take Action to End Diabetes".
  • Diabetes Awareness Month reminds us of the importance of educating ourselves, spreading awareness and taking action, as every action brings us closer to a future without diabetes."
  • Diabetes Canada is the registered national charitable organization that is making the invisible epidemic of diabetes visible and urgent.

American Diabetes Association Releases Study on Access Barriers to Continuous Glucose Monitors at Cost of Care Summit

Retrieved on: 
Monday, November 8, 2021
Mortality, Quality of life, ADA, Color, CGM, Medicare, CGMS-A, Education, African Americans, Income, Diabetes, Research, Multimedia, Program, Health Management Associates, Black, Insulin, Medicine, Continuous glucose monitor, American Diabetes Association, Prediabetes, Patient, Risk, Life, Health equity, Pharmaceutical industry, Health insurance

ARLINGTON, Va., Nov. 8, 2021 /PRNewswire/ -- Last week, at its first-ever Cost of Care Summit, the American Diabetes Association(ADA) shared the results of a new study on Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race.

Key Points: 
  • ARLINGTON, Va., Nov. 8, 2021 /PRNewswire/ -- Last week, at its first-ever Cost of Care Summit, the American Diabetes Association(ADA) shared the results of a new study on Health Equity and Diabetes Technology: A Study of Access to Continuous Glucose Monitors by Payer and Race.
  • Among all surveyed populations, Black Americans experience face the greatest access barriers to CGM access.
  • The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive.
  • Join the fight with us on Facebook ( American Diabetes Association ), Spanish Facebook ( Asociacin Americana de la Diabetes ),Twitter ( @AmDiabetesAssn ), andInstagram ( @AmDiabetesAssn ).